PRKN and Parkinson disease: Despite the well-known role of dysfunction of Pink1 and Parkin proteins in the pathogenesis of PD, there are currently only a few preclinical studies of the effectiveness of compounds activating the action of these proteins, so it will be possible to state what effect this therapy will have in the treatment of patients with PD no sooner than in 10–15 years.